MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517080407 A) filed by Lepu Biopharma Co. Ltd., Shanghai, on Aug. 25, for 'linker drug, and preparation method and use of antibody-drug conjugate thereof.'
Inventor(s) include Li, Hongfeng; Liu, Wei; Ma, Tian; Liu, Wenchao; Wu, Xiangyu; Wang, Yanchun; Xu, Zhenyi; Hu, Chaohong; and Qin, Minmin.
The application for the patent was published on Sept. 12, under issue no. 37/2025.
According to the abstract released by the Intellectual Property India: "A linker-drug conjugate, an antibody-drug conjugate, and a preparation method therefor and the use thereof. The linker-drug conjugate has a structure as shown in formula I, i.e., M-X-D (formula I), wherein M is a chemical structure comprising a maleimide (m) fragment or a cyclooctyne fragment, X is a linker fragment composed of 1-5 amino acids or derivatives thereof, and D is a cytotoxin. The linker-drug conjugate can release Payload by means of an enzymatic hydrolysis reaction in the case of removal of hydrophobic structure PAB, which can not only reduce the hydrophobicity of the Linker-Drug and reduce the content of a polymer produced in the preparation of ADC, but also can exhibit the corresponding cell killing activity."
The patent application was internationally filed on Jan. 29, 2024, under International application No.PCT/CN2024/074508.
Disclaimer: Curated by HT Syndication.
